Page last updated: 2024-10-25

ciprofloxacin and Degenerative Diseases, Central Nervous System

ciprofloxacin has been researched along with Degenerative Diseases, Central Nervous System in 1 studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers."5.69Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Salomon-Zimri, S1
Pushett, A1
Russek-Blum, N1
Van Eijk, RPA1
Birman, N1
Abramovich, B1
Eitan, E1
Elgrart, K1
Beaulieu, D1
Ennist, DL1
Berry, JD1
Paganoni, S1
Shefner, JM1
Drory, VE1

Trials

1 trial available for ciprofloxacin and Degenerative Diseases, Central Nervous System

ArticleYear
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2023, Volume: 24, Issue:3-4

    Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression;

2023